Study on syndrome evolution of re-positive patients infected with SARS-CoV-2 Omicron variant BA.1

  • role: First author第一作者
  • Affiliation:

    Henan University of Chinese Medicine, Zhengzhou 450002, China

  • Introduction:
WANG Mengmeng1,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

CUI Yinglin2,  
  • role: Corresponding author通信作者
  • Affiliation:

    Henan University of Chinese Medicine, Zhengzhou 450002, China

  • Email:gds349@126.com
  • Introduction:Prof. GUAN Dongsheng, Ph.D., Chief Physician, Doctoral Supervisor. Henan University of Chinese Medicine, No.2 Dongfeng Road, Jinshui District, Zhengzhou 450002. E-mail: gds349@126.com
GUAN Dongsheng1*,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

DU Xuzhao2,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

ZHANG Zhixin2,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

ZHOU Chaofeng2,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

YANG Ling2,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

QIAO Mingliang2,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

LI Bin2,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

XIE Hongxia2,  
  • Affiliation:

    The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450053, China

ZHANG Wentao2

résumé

ObjectiveWe aimed to explore the syndrome evolution of re-positive COVID-19 patients who were infected with SARS-CoV-2 Omicron variant BA.1 and to provide a reference for Chinese medicine-based treatment of COVID-19.MethodsCollecting the medical records of patients infected with Omicron variant BA.1 from January to March 2022 in Qiboshan Hospital and Port Hospital in Henan Province. Selecting 61 patients who have re-positive after infection as the re-positive group, and 60 normal negative patients admitted at the same time as the control group. The TCM syndromes were diagnosed in 1, 4, 7, 14, 21, and 30 days after hospital admission.ResultsExamination of syndrome evolution in the control group revealed: exterior syndrome, dampness-heat encumbering the lung syndrome, epidemic toxins blocking the lungs, and deficiency syndrome(mainly qi and yin deficiency). Similarly, examination of symptomatic evolution in the re-positive group revealed dampness-heat encumbering the lung syndrome, epidemic toxins blocking the lungs, and deficiency syndrome(mainly qi and yin deficiency). In the re-positive group, the syndrome changed from excess to deficiency in (20.00±8.54) days, and the final successful turning negative occurred after (31.79±7.93) days. Re-positive occurred after (28.27±8.55) days. In the control group, the syndrome type changed from excess to deficiency in (12.89±2.77) days, and finally turned negative after (18.78±6.29) days.ConclusionSyndrome evolution in re-positive patients is as follows: 1-14 days are dominated by dampness and heat encumbering the lung syndrome, which then develops to the extreme stage of epidemic toxins blocking the lung syndrome. The late stage and recovery period of the disease in 14-30 days mainly involve a deficiency syndrome, mostly deficiency of qi and yin. The course of disease in re-positive patients is longer than that in patients with common turning negative conversion.

mots-clés

COVID-19;Omicron variant BA.1;re-positive;syndrome evolution;disease course

References

  1. [1].
    中华人民共和国国家卫生健康委员会办公厅.《关于对新型冠状病毒感染实施“乙类乙管”的总体方案》解读问答[EB/OL].( 2022-12-26)[2022-12-30]..
  2. [2].
    ARAF Y, AKTER F, TANG YD, et al. Omicron variant of SARS-CoV-2:genomics, transmissibility, and responses to current COVID-19 vaccines[J].J Med Virol,2022,94(5):1825-1832.
  3. [3].
    TORJESEN I. Covid-19: omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear[J/OL].BMJ,2021,375:n2943[2022-10-05]..
  4. [4].
    TIAN DD, SUN YH, ZHOU JM, et al. The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape[J/OL]. Front Immunol,2021,12:751778[2022-10-05]..
  5. [5].
    国家卫生健康委员会. 2020年5月7日新闻发布会文字实录[EB/OL].(2020-05-07)[2022-10-05]..
  6. [6].
    国家卫生健康委办公厅,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第八版)[EB/OL].(2020-08-18)[2022-10-05]..
  7. [7].
    国家卫生健康委办公厅,国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行 第八版 修订版)[EB/OL].(2021-04-14)[2022-10-05]..
  8. [8].
    周静,陈晶晶,张念志,等.安徽省144例新型冠状病毒肺炎患者中医证候特征[J].中国实验方剂学杂志,2020,26(12):28-34.
  9. [9].
    陆炜青,钱刘兰,翟洪军,等.基于潜在类别分析的新型冠状病毒肺炎患者中医证候分类研究[J].中医杂志,2021,62(4):296-302.
  10. [10].
    崔应麟,关东升,王梦梦,等.新型冠状病毒肺炎“复阳”患者中医体质类型分析[J].中华中医药学刊,2022,40(11):13-15.
  11. [11].
    柴可群,黄飞华,李亚平,等.中药干预新型冠状病毒肺炎的临床研究[J].中华中医药杂志,2021,36(12):7458-7462.
  12. [12].
    王源,黄东晖,王慧贤,等.中西医结合治疗80例新型冠状病毒肺炎重型及危重型患者疗效观察[J].北京中医药大学学报,2022,45(6):555-562.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website